γ-干扰素作为免疫抑制指标在双相抑郁中的研究

Study of interferon-gamma as an indicator of immune suppression in bipolar depression

目的探索双相抑郁患者血浆中γ-干扰素的水平以及它与临床特征、疗效的关系。方法选取60例双相障碍抑郁发作期患者(患者组)及匹配的健康对照62名(对照组),于治疗前及治疗后第12周末评估患者的临床症状及检测血浆γ-干扰素浓度。结果患者组γ-干扰素浓度低于对照组(P <0. 05);γ-干扰素浓度与临床特征(HAMD-17总分、HAMA总分等)、疗效(HAMD-17减分率)无相关性(P> 0. 05)。经过急性期治疗,不管疗效如何,双相抑郁γ-干扰素浓度均降低(P <0. 05)。结论γ-干扰素或可作为反映双相抑郁患者免疫抑制状况的重要指标,且其浓度受到药物治疗的影响。

Objective To explore the plasma level of interferon-gamma in patients with bipolar depression （BDD） and the relationship between interferon-gamma and the clinical features, curative effect. Methods 60 BDD patients （BDD group） and 62 healthy controls （control group） whose gender, age and education level were matched with patients, were selected and assessed with clinical features and plasma interferon-gamma levels at baseline and at the end of the 12^th week after treatment. Results Interferon-gamma level in BDD group was significantly lower than that in control group （ P 〈 0.05 ）. There existed no correlation between interferon-gamma level and clinical features （total scores of HAMD-17 and HAMA）, curative effect （reductive rate of HAMD-17）. Regardless of therapeutic effect, interferon-gamma level significantly decreased in BDD group after acute phase treatment （ P 〈 0. 05 ）. Conclusion Interferon-gamma may be an important marker reflecting immune suppression in patients with BDD which could be influenced by pharmacotherapy.